- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06032546
Uno studio per valutare i cambiamenti nell'attività della malattia, negli eventi avversi e nel modo in cui il farmaco si muove attraverso il corpo in partecipanti adulti che vivono con il virus dell'immunodeficienza umana (HIV) che ricevono un'infusione endovenosa (IV) di Budigalimab e/o ABBV-382
Uno studio di fase 2, multicentrico, randomizzato, in doppio cieco, controllato con placebo per valutare l'efficacia, la sicurezza, la tollerabilità e la farmacocinetica di Budigalimab e/o ABBV-382 in persone affette da HIV in terapia antiretrovirale stabile sottoposte a interruzione del trattamento analitico
Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic disease requiring lifelong therapy. The purpose of this study is to assess change in disease activity, adverse events, tolerability, and how the drug moves through the body.
Budigalimab and ABBV-382 are investigational drugs being developed for the treatment of HIV disease. In Part 1, participants are placed in 1 of 5 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 7 chance that participants will be assigned to placebo (A placebo is not a drug and it is not expected to have any chemical effects on your body and it is not designed to treat any disease or illness). In Part 2, eligible participants will be placed in an open-label arm to receive Budigalimab. Approximately 160 adult participants living with HIV disease on stable antiretroviral therapy (ART) willing to undergo Analytical Treatment Interruption (ATI) will be enrolled at approximately 90 sites worldwide.
In Part 1, participants will receive 4 doses of intravenous (IV) budigalimab or placebo combined with 3 doses of IV ABBV-382 or placebo for an 8 week dosing period. In Part 2, participants will receive 4 doses of open-label subcutaneous (SC) Budigalimab for a 6 week dosing period. Participants need to be stable on antiretroviral therapy to participate in the study. If participant qualifies to the study, on the day they receive the first injection, participants will be asked to stop antiretroviral medications (also referred to as analytical treatment interruption or ATI) for 112 weeks or until meeting specific criteria to restart antiretroviral medications. Participants will undergo a closely monitored ART interruption. Protocol-defined ART restart criteria includes participant's request. Participants will be followed for up to approximately 112 weeks.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. There will be an option for virtual or home health visits for some of the follow-up visits. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Brussels Capital
-
Anderlecht, Brussels Capital, Belgio, 1070
- Universite Libre de Bruxelles - Hopital Erasme /ID# 257433
-
Brussels, Brussels Capital, Belgio, 1000
- CHU Saint Pierre /ID# 257447
-
Brussels, Brussels Capital, Belgio, 1200
- Cliniques Universitaires UCL Saint-Luc /ID# 257444
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Belgio, 9000
- UZ Gent /ID# 257446
-
-
-
-
São Paulo
-
São Paulo, São Paulo, Brasile, 04037-030
- Ricardo Diaz Scientific Solution /ID# 257335
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 2T1
- Spectrum Health Vancouver /ID# 260791
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Ottawa Hospital Research Institute /ID# 256993
-
Toronto, Ontario, Canada, M5G 2C4
- Duplicate_Toronto General Hospital /ID# 256994
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3J1
- McGill University Health Centre - Glen Site. /ID# 256992
-
Québec, Quebec, Canada, G1V 4G2
- CHU de Quebec-Université Laval hôpital CHUL /ID# 261611
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4P 0W5
- Regina General Hospital - Infectious Disease Clinic /ID# 260243
-
-
-
-
-
Paris, Francia, 75012
- AP-HP - Hopital Saint-Antoine /ID# 258090
-
Paris, Francia, 75020
- AP-HP - Hopital Tenon /ID# 258091
-
-
-
-
-
Berlin, Germania, 10439
- zibp-Zentrum fuer Infektiologie /ID# 257110
-
-
Hesse
-
Frankfurt am Main, Hesse, Germania, 60596
- Infektiologikum /ID# 257112
-
-
North Rhine-Westphalia
-
Bonn, North Rhine-Westphalia, Germania, 53127
- Universitaetsklinikum Bonn /ID# 257113
-
-
-
-
-
Tokyo, Giappone, 108-8639
- IMSUT Hospital, The Institute of Medical Science, The University of Tokyo /ID# 265344
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Giappone, 460-0001
- NHO Nagoya Medical Center /ID# 261433
-
-
Osaka
-
Osaka, Osaka, Giappone, 540-0006
- National Hospital Organization Osaka National Hospital /ID# 261520
-
-
-
-
-
Modena, Italia, 41124
- Azienda Ospedaliero-Universitaria di Modena /ID# 257411
-
-
Milano
-
Milan, Milano, Italia, 20132
- IRCCS Ospedale San Raffaele /ID# 259820
-
Milan, Milano, Italia, 20162
- ASST Grande Ospedale Metropolitano Niguarda /ID# 257410
-
-
Napoli
-
Naples, Napoli, Italia, 80131
- Azienda Ospedaliera Universitaria Federico II - Naples /ID# 257412
-
-
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polonia, 85-030
- Wojewodzki Szpital Obserwacyjno-Zakazny im. Tadeusza Browicza /ID# 259184
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Polonia, 80-405
- Punkt Zdrowia /ID# 257950
-
-
-
-
-
San Juan, Porto Rico, 00909-1711
- Clinical Research Puerto Rico /ID# 256956
-
San Juan, Porto Rico, 00909
- HOPE Clinical Research /ID# 257487
-
-
-
-
Greater London
-
London, Greater London, Regno Unito, NW3 2QG
- Royal Free Hospital /ID# 257453
-
London, Greater London, Regno Unito, SE1 9RT
- Dup_Guys and St Thomas NHS Foundation Trust - Guy's Hospital /ID# 257761
-
-
-
-
-
Barcelona, Spagna, 08036
- Hospital Clinic de Barcelona /ID# 257269
-
Madrid, Spagna, 28034
- Hospital Universitario Ramon y Cajal /ID# 257266
-
Madrid, Spagna, 28046
- Hospital Universitario La Paz /ID# 257170
-
-
Barcelona
-
Badalona, Barcelona, Spagna, 08916
- Hospital Universitario Germans Trias i Pujol /ID# 257268
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35222-2309
- University of Alabama at Birmingham, 1917 Research Clinic /ID# 257549
-
-
California
-
Bakersfield, California, Stati Uniti, 93301
- Franco Felizarta, Md /Id# 256927
-
Beverly Hills, California, Stati Uniti, 90211
- AHF Research Center /ID# 257025
-
Long Beach, California, Stati Uniti, 90813-3267
- Long Beach Education and Research Consultants /ID# 257552
-
Los Angeles, California, Stati Uniti, 90027
- AHF Healthcare Center- Hollywood /ID# 257026
-
Los Angeles, California, Stati Uniti, 90028-6213
- Los Angeles LGBT Center /ID# 258407
-
Los Angeles, California, Stati Uniti, 90036
- Ruane Clinical Research Group /ID# 256932
-
Palm Springs, California, Stati Uniti, 92262
- Palmtree Clinical Research Inc. /Id# 258409
-
San Francisco, California, Stati Uniti, 94102
- Optimus Medical /ID# 257182
-
San Francisco, California, Stati Uniti, 94115-3037
- Quest Clinical Research /ID# 256928
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20017
- Washington Health Institute /ID# 259336
-
-
Florida
-
DeLand, Florida, Stati Uniti, 32720-0920
- Midland Florida Clinical Research Center /ID# 257101
-
Fort Lauderdale, Florida, Stati Uniti, 33308
- Ahf Healthcare Center - Northpoint /ID# 256934
-
Ft. Pierce, Florida, Stati Uniti, 34982
- Midway Immunology and Research Center /ID# 256930
-
Miami, Florida, Stati Uniti, 33147
- Advanced Pharma CR, LLC /ID# 259335
-
Orlando, Florida, Stati Uniti, 32803
- Orlando Immunology Center /ID# 256931
-
Orlando, Florida, Stati Uniti, 32806-3300
- Bliss Health /ID# 257827
-
Tampa, Florida, Stati Uniti, 33614
- Baycare Medical Group - Tampa /ID# 256953
-
Vero Beach, Florida, Stati Uniti, 32960-6541
- The Pierone Research Institute /ID# 257022
-
West Palm Beach, Florida, Stati Uniti, 33407
- Triple O Research Institute /ID# 256929
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30308
- Winship At Emory University Hospital Midtown /ID# 258410
-
Decatur, Georgia, Stati Uniti, 30033
- Metro Infectious Disease Consultants /ID# 256955
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60613-2010
- Howard Brown Health Center /ID# 257485
-
-
Massachusetts
-
Springfield, Massachusetts, Stati Uniti, 01105-1406
- Claudia T. Martorell MD LLC dba The Research Institute /ID# 259155
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64111
- KC CARE Health Center - Midtown South /ID# 257178
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89106
- Las Vegas Research Center /ID# 257619
-
-
New Jersey
-
Camden, New Jersey, Stati Uniti, 08103
- Cooper University Health Care - Camden /ID# 258133
-
Newark, New Jersey, Stati Uniti, 07102
- Saint Michael's Medical Center /ID# 258802
-
Somers Point, New Jersey, Stati Uniti, 08244
- South Jersey Infectious Disease /ID# 257840
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87106
- The University of New Mexico /ID# 257533
-
-
New York
-
Syracuse, New York, Stati Uniti, 13215
- Suny Upstate University Hospital Community Campus /ID# 257847
-
The Bronx, New York, Stati Uniti, 10461
- Jacobi Medical Center /ID# 257849
-
The Bronx, New York, Stati Uniti, 10467
- Montefiore Medical Center /ID# 257792
-
-
North Carolina
-
Greenville, North Carolina, Stati Uniti, 27834
- East Carolina University - Brody School of Medicine /ID# 257544
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Atrium Health Wake Forest Baptist Medical Center /ID# 257542
-
-
Texas
-
Austin, Texas, Stati Uniti, 78705-3326
- Central Texas Clinical Research /ID# 256920
-
Dallas, Texas, Stati Uniti, 75208-4599
- Prism Health North Texas - Oak Cliff Health Center /ID# 256933
-
Dallas, Texas, Stati Uniti, 75246
- North Texas Infectious Diseases Consultants, P.A /ID# 257592
-
Dallas, Texas, Stati Uniti, 75390-7208
- University of Texas Southwestern Medical Center /ID# 257551
-
Fort Worth, Texas, Stati Uniti, 76104
- Texas Center for Infectious Disease Associates /ID# 257183
-
Houston, Texas, Stati Uniti, 77098-3900
- The Crofoot Research Center, Inc /ID# 256921
-
Longview, Texas, Stati Uniti, 75605
- DCOL Center for Clinical Research /ID# 257093
-
-
Wisconsin
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Wisconsin Medical Center /ID# 257498
-
-
-
-
Gauteng
-
Johannesburg, Gauteng, Sud Africa, 2001
- Wits RHI Research Centre /ID# 257354
-
Johannesburg, Gauteng, Sud Africa, 2013
- Perinatal HIV Research Unit (PHRU) /ID# 257350
-
Johannesburg, Gauteng, Sud Africa, 2092
- Clinical HIV Research Unit (CHRU) /ID# 257358
-
Johannesburg, Gauteng, Sud Africa, 2193
- Ezintsha Research Centre /ID# 257391
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- A condition of general good health in the opinion of the investigator, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG).
- Must be on antiretroviral therapy (ART) for at least 12 months prior to screening and on a stable ART regimen for at least 8 weeks prior to screening (current ART regimen cannot include an Non-nucleoside reverse transcriptase inhibitor [NNRTI] or long-acting ART).
- Negative human immuno-deficiency virus (HIV)-2 antibody (Ab)
- Cluster of differentiation 4 (CD4+) T cell count >= 500 cells/μL at screening and no known evidence of CD4+ T cell count < 500 cells/μL in the last 12 months prior to screening
- Participant must have plasma HIV-1 ribonucleic acid (RNA) below the lower limit of quantitation (LLOQ) at screening and for at least 12 months prior to screening
Exclusion Criteria:
- Prior exposure to long acting antiretrovirals within 24 weeks or within a period defined by 5 half-lives, whichever is longer, prior to randomization and prior to the first dose of study drug.
- History of CD4+ T cell nadir of <= 200 cells/μL during chronic HIV infection.
- History of medical disorders (other than HIV-1 infection) that, in the opinion of the investigator, might expose the participant to undue risk of harm, confound study outcomes or prevent the participant from completing the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore placebo: Arm A: Placebo
Participants will receive budigalimab placebo on Day 1, and Weeks 2, 4, and 6 in combination with ABBV-382 matching placebo on Day 1 and Weeks 4 and 8. |
IV Infusion IV Infusion |
|
Sperimentale: Arm B: Budigalimab Dose A
Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 matching placebo Day 1 and Weeks 4 and 8. |
IV Infusion Intravenous (IV) Infusion
Altri nomi:
Subcutaneous (SC) Injection
Altri nomi:
|
|
Sperimentale: Arm C: ABBV-382 Dose A
Participants will receive budigalimab placebo on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose A on Day 1 and Weeks 4 and 8. |
IV Infusion IV Infusion |
|
Sperimentale: Arm D: Budigalimab Dose A + ABBV-382 Dose B
Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose B on Day 1 and Weeks 4 and 8. |
Intravenous (IV) Infusion
Altri nomi:
Subcutaneous (SC) Injection
Altri nomi:
IV Infusion |
|
Sperimentale: Arm E: Budigalimab Dose A + ABBV-382 Dose A
Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose A on Day 1 and Weeks 4 and 8. |
Intravenous (IV) Infusion
Altri nomi:
Subcutaneous (SC) Injection
Altri nomi:
IV Infusion |
|
Sperimentale: Arm F: Budigalimab Dose B
Participants will receive open-label budigalimab Dose B on Day 1 and Weeks 2, 4, and 6 (Note, no ABBV-382 or placebo will be administered). |
Intravenous (IV) Infusion
Altri nomi:
Subcutaneous (SC) Injection
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Participants With Viral Control Without Antiretroviral Therapy (ART) Restart
Lasso di tempo: Week 24
|
Percentage of participants who achieve viral control (viral load < 1000 copies/mL) without ART restart at Week 24. |
Week 24
|
|
Number of Participants With Adverse Events (AEs)
Lasso di tempo: Up to approximately Week 112
|
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
Up to approximately Week 112
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Median Peak Log10 Viral Load (At Rebound) Prior to Re-Starting ART
Lasso di tempo: Up to 112 weeks
|
The median peak log10 viral load (at rebound) before re-starting ART. |
Up to 112 weeks
|
|
Median Time to First Rebound to ≥ 1000 Copies/mL During ART Interruption
Lasso di tempo: Up to 112 weeks
|
The median time to first rebound to ≥ 1000 copies/mL during ART interruption. |
Up to 112 weeks
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: ABBVIE INC., AbbVie
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- M19-965
- 2023-505900-53-00 (Altro identificatore: EU CT)
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Periodo di condivisione IPD
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Criteri di accesso alla condivisione IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .